• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

14.49 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
April 21, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
February 27, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
February 19, 2025
From Kaskela Law LLC
Via Business Wire
News headline image
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
February 19, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 19, 2025 ↗
February 19, 2025
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts ↗
January 13, 2025
 
Via Benzinga
News headline image
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics ↗
November 12, 2024
 
Via Benzinga
News headline image
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
February 10, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025
February 03, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
January 12, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts ↗
November 12, 2024
 
Via Benzinga
News headline image
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) ↗
November 12, 2024
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights ↗
November 07, 2024
 
Via Benzinga
News headline image
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 02, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? ↗
December 13, 2024
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks. 
Via Benzinga
News headline image
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
November 06, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
November 01, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts ↗
October 11, 2024
 
Via Benzinga
News headline image
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
October 28, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug ↗
October 17, 2024
Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA... 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday ↗
October 17, 2024
 
Via Benzinga
News headline image
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
October 17, 2024
Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
October 04, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm
September 17, 2024
From Kaskela Law LLC
Via Business Wire
News headline image
UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
September 03, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
September 03, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium
September 03, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
August 30, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
August 08, 2024
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
August 08, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap